The content is available as a PDF (107.1 KB).
Footnotes
Disclosure
Conflicts of interest: none
References
- 1.Laniosz V, Lehman JS, Poland GA, Wetter DA. Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses. Int J Dermatol. 2016;55:599–607. doi: 10.1111/ijd.13140. [DOI] [PubMed] [Google Scholar]
- 2.Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical trial group et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Baden LR, El Sahly HM, Essink B, COVE Study Group et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;30:NEJMoa2035389. doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Voysey M, Clemens SAC, Madhi SA, Oxford COVID vaccine trial group et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Centers for disease control and prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States.https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.(accessed 28 Jan 2021).
- 6.Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52. doi: 10.1136/annrheumdis-2019-215882. [DOI] [PubMed] [Google Scholar]
- 7.Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol. 2020;82:e235–6. doi: 10.1016/j.jaad.2020.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rubin LG, Levin MJ, Ljungman P, et al. Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18. doi: 10.1093/cid/cit816. [DOI] [PubMed] [Google Scholar]
- 9.Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95:e1999–2008. doi: 10.1212/WNL.0000000000010380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129:2202–10. doi: 10.1038/jid.2009.27. [DOI] [PubMed] [Google Scholar]
- 11.Neri I, Greco A, Bassi A, et al. Bullous pemphigoid in infant post vaccination: myth or reality? Int J Immunopathol Pharmacol. 2016;29:295–9. doi: 10.1177/0394632015603796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–9. doi: 10.1038/s41586-020-2814-7. [DOI] [PubMed] [Google Scholar]
- 13.Moro F, Fania L, Sinagra JLM, Salemme A, Zenzo GD. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10:1432. doi: 10.3390/biom10101432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev. 2011;10:527–35. doi: 10.1016/j.autrev.2011.04.003. [DOI] [PubMed] [Google Scholar]
- 15.Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051. doi: 10.1016/j.jtauto.2020.100051. [DOI] [PMC free article] [PubMed] [Google Scholar]